Here is the Facebook message from Cynthia posted 12/26/2013:
Dear Shareholders,
Happy and healthy New Year greetings to you and your families. I believe the hard work of the past year has laid the foundation for Viropro to move forward and maximize value for its shareholders. Viropro's plans for 2014 include an up-listing to a more significant stock exchange and identifying significant partners for our biosimilars and Alpha Biologics.
Last December 2012, the total market capitalization of Viropro was less than US $4 million. Today, the Viropro market capitalization exceeds US $15 million. I want to thank Mr. Kishin Binwani, Mr. Ashfaq Ahmed and Dr. Zhongling Feng for their daily work at excellence.
Highlights of accomplishments for the past twelve months include:
Two years (2011-12) of accounting are finally completed and audited financials for these years is underway. Viropro is working with a team to draft the 10Ks so we can become fully reporting.
Viropro worked closely with the outstanding leadership at Malaysia Biotech Corporation and signed a significant agreement with Argentina based Biosidus to bring their products to Malaysia. Bravo to Malaysia Biotech Corp!
Viropro and Therapix together will build a platform for technolgies and add dynamic professionals to Viropro management.
Plans for adding significant operational and scientific talent to Alpha Biologics, as well as funding from Hyderabad based Vivo Bio Tech, will allow Alpha Biologics to become operational for the first time.
Thank you for your support, ideas and suggestions. We look forward to the annual meeting in early 2014.
Most Sincerely,
Cynthia Ekberg Tsai
Chairman and CEO
Viropro
AI
Market Data 
Markets 
